Page 14 - Study Design News Today

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...

Primary endpoint met: deucrictibant significantly reduced attack rate The primary endpoint of the CHAPTER-1 study measured the time-normalized number of investigator-confirmed HAE attacks during the treatment period. The monthly attack rate was reduced by 84.5% (p=0.0008) compared to placebo in participants who received 40 mg/day of deucrictibant. Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to place

This cross-national study reveals that 85% of young adults across four countries have been exposed to e-cigarette advertising, despite existing regulations. The research also found a significant association between the level of media exposure and the likelihood of e-cigarette use among the youth.

Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.

Expert oncologist Yasir Elamin, MD, shares data from the BRIGHTSTAR trial and considers how it may inform real-world use of brigatinib in patient with ALK-rearranged metastatic non–small cell lung cancer.

/PRNewswire/ -- Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardiometabolic health, today announced...

This open-label, single-group, phase 3 trial evaluates eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in adults with hereditary am

The Global Non-Alcoholic Steatohepatitis Clinical Trials Market Size will be worth around US$ 2.6 billion in 2022, according to Future Market Insights. However, between 2022 and 2032, the market is likely to develop significantly, with a projected growth rate of 7%, which is higher than the historical increase. With...

Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema Real-world data reinforce that...

‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...